Progenics Announces Publication of Pivotal Trial of AZEDRA® (iobenguane I 131) in The Journal of Nuclear Medicine
09 oct. 2018 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and...
Progenics Reports Results of Phase 2/3 Trial of PSMA PET Imaging Agent PyL for the Detection of Prostate Cancer
05 oct. 2018 07h30 HE
|
Progenics Pharmaceuticals Inc.
-PyL highly sensitive, 93-99%, in reliably detecting metastatic prostate cancer lesions and highly specific, 96-99%, in confirming the absence of pelvic lymph node disease- -Study data highlights the...
Progenics Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
25 sept. 2018 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and...
Progenics Announces Addition of AZEDRA® (iobenguane I 131) to National Comprehensive Cancer Network Guidelines for Pheochromocytoma and Paraganglioma
17 sept. 2018 06h00 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and...
Progenics Pharmaceuticals Reports Top Line Phase 3 Data for Prostate Cancer Imaging Agent 1404
12 sept. 2018 16h01 HE
|
Progenics Pharmaceuticals Inc.
-Meets Co-Primary Endpoint of Specificity; 1404 Successfully Identifies Patients Without Clinically Significant Prostate Cancer--Co-Primary Endpoint of Sensitivity to Identify Patients with Clinically...
Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
07 août 2018 22h12 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today the pricing of an underwritten public offering of 9,090,909 primary shares of its common...
Progenics Pharmaceuticals Announces Proposed Public Offering of Common Stock
07 août 2018 16h01 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today that it is offering to sell shares of its common stock in an underwritten public offering...
Following Azedra’s Approval, Progenics Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Update
31 juil. 2018 16h30 HE
|
Progenics Pharmaceuticals Inc.
AZEDRA® (iobenguane I 131) Approved by U.S. Food and Drug Administration (FDA); U.S. Promotion CommencesTop-Line Data from Phase 3 Trial for PSMA-Targeted SPECT/CT Imaging Agent 1404 Expected in...
Progenics Pharmaceuticals Announces FDA Approval for AZEDRA® (iobenguane I 131) to Treat Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma
30 juil. 2018 21h46 HE
|
Progenics Pharmaceuticals Inc.
The First FDA-Approved Treatment for These Rare, Life-Threatening Neuroendocrine Cancers in Patients Aged 12 and Older Company to Host Conference Call Tomorrow at 8:00 AM ET NEW YORK, July 30, 2018...
Progenics Pharmaceuticals Completes Enrollment of Phase 2/3 Clinical Trial of PSMA-Targeted PET/CT Imaging Agent PyL™ in Prostate Cancer
26 juin 2018 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, June 26, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging technology for targeting and treating...